Market closed
Collegium Pharmaceutical/$COLL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Ticker
$COLL
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
197
Website
COLL Metrics
BasicAdvanced
$982M
Market cap
14.08
P/E ratio
$2.16
EPS
0.81
Beta
-
Dividend rate
Price and volume
Market cap
$982M
Beta
0.81
52-week high
$40.95
52-week low
$28.97
Average daily volume
514K
Financial strength
Current ratio
0.966
Quick ratio
0.758
Long term debt to equity
395.833
Total debt to equity
423.942
Interest coverage (TTM)
3.08%
Management effectiveness
Return on assets (TTM)
10.35%
Return on equity (TTM)
42.89%
Valuation
Price to earnings (TTM)
14.076
Price to revenue (TTM)
1.642
Price to book
4.19
Price to tangible book (TTM)
-1.14
Price to free cash flow (TTM)
5.114
Growth
Revenue change (TTM)
9.62%
Earnings per share change (TTM)
757.11%
3-year revenue growth (CAGR)
22.53%
3-year earnings per share growth (CAGR)
-7.03%
What the Analysts think about COLL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
COLL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
COLL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
COLL News
AllArticlesVideos
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Seeking Alpha·4 weeks ago
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)
GlobeNewsWire·1 month ago
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Collegium Pharmaceutical stock?
Collegium Pharmaceutical (COLL) has a market cap of $982M as of December 21, 2024.
What is the P/E ratio for Collegium Pharmaceutical stock?
The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 14.08 as of December 21, 2024.
Does Collegium Pharmaceutical stock pay dividends?
No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Collegium Pharmaceutical dividend payment date?
Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.
What is the beta indicator for Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.